Buscar
Mostrando ítems 1-10 de 37
Multicenter evaluation of ceftolozane/tazobactam for serious infections caused by carbapenem-resistant pseudomonas aeruginosa
(Oxford University Press, 2017)
A multicenter, retrospective study of patients infected with carbapenem-resistant Pseudomonas aeruginosa who were treated with ceftolozane/tazobactam was performed. Among 35 patients, pneumonia was the most common indication ...
Perfil de susceptibilidad in vitro de Enterobacterias BLEES positivas aisladas de muestras clínicas frente a ceftolozane/tazobactam
(Pontificia Universidad Javeriana, 2019)
Multicenter evaluation of ceftolozane/tazobactam for serious infections caused by carbapenem-resistant pseudomonas aeruginosa
(Oxford University Press, 2017)
A multicenter, retrospective study of patients infected with carbapenem-resistant Pseudomonas aeruginosa who were treated with ceftolozane/tazobactam was performed. Among 35 patients, pneumonia was the most common indication ...
Comparative In Vitro Activity of Ceftolozane/Tazobactam against Clinical Isolates of Pseudomonas aeruginosa and Enterobacterales from Five Latin American Countries
(2022)
Background: Ceftolozane/tazobactam (C/T) is a combination of an antipseudomonal oxyiminoaminothiazolyl cephalosporin with potent in vitro activity against Pseudomonas aeruginosa and tazobactam, a known β-lactamase inhibitor. ...
Caracterización genómica asociada a la resistencia a antibióticos de aislamientos clínicos colombianos de Pseudomonas aeruginosa no susceptibles a Ceftolozane/tazobactam
(MedicinaUniversidad El BosqueFacultad de Medicina, 2021)
P. aeruginosa es un patógeno de alto riesgo causante de 32.600 infecciones en pacientes hospitalizados y más de 2.700 muertes anualmente en USA. Causa infecciones asociadas al cuidado de la salud, como neumonía asociada a ...
Perfil de susceptibilidad in vitro de Enterobacterias BLEES positivas aisladas de muestras clínicas frente a ceftolozane/tazobactam
Las Enterobacterias son un grupo grande y heterogéneo de bacterias gramnegativas, las cuales se caracterizan por su capacidad de producir infecciones en pacientes inmunocompetentes e inmunosuprimidos tanto de la comunidad ...
Perfil de susceptibilidad In Vitro de Pseudomonas aeruginosa frente a Ceftolozane/Tazobactam
(Pontificia Universidad Javeriana, 2019)
Real-world Performance of Susceptibility Testing for Ceftolozane/Tazobactam Against Non-Carbapenemase-Producing Carbapenem-Resistant Pseudomonas aeruginosa
(2021)
Ceftolozane/tazbactam (C/T) is a potent anti-pseudomonal agent that has clinical utility against infections caused by non-carbapenemase producing carbapenem-resistant P. aeruginosa (non-CP-CR-PA). Accurate, precise and ...
Higher MICs (>2 mg/L) Predict 30-Day Mortality in Patients With Lower Respiratory Tract Infections Caused by Multidrug- and Extensively Drug-Resistant Pseudomonas aeruginosa Treated With Ceftolozane/Tazobactam
(2019)
Background: Ceftolozane/tazobactam (C/T) efficacy and safety in ventilator-associated pneumonia (VAP) is being evaluated at a double dose by several trials. This dosing is based on a pharmacokinetic (PK) model that ...
Molecular mechanisms leading to ceftolozane/tazobactam resistance in clinical isolates of Pseudomonas aeruginosa from five Latin American countries
(2022)
Objectives: Identify molecular mechanisms responsible for the in vitro non-susceptibility to ceftolozane/tazobactam (TOL) in a group of 158 clinical isolates of Pseudomonas aeruginosa from five Latin American countries ...